TWO · 6748.TWO
ACRO Biomedical Co., Ltd.
NT$182.50-NT$11.50 (-5.93%)
ACRO Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.13% below the high.
Loading market information…
TAI · 4737.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Bionime Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Bionime Corporation’s forward annual dividend is NT$1.82 per share, paid annual. The forward yield is 2.77% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Bionime Corporation’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of NT$0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bionime Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bionime Corporation, headquartered in Taichung, Taiwan, specializes in the development, production, and global distribution of medical instruments. The company maintains a significant international presence, serving markets in countries such as China, Switzerland, the United States, Algeria, and Egypt. Its primary product line features blood glucose monitoring systems, along with essential complementary items like test strips and lancing devices. These healthcare solutions are supplied to a varied customer base, including hospitals, pharmacies, and other medical equipment enterprises. Beyond its core medical device business, Bionime also engages in providing biotechnology-related services, performing pharmaceutical analysis, and marketing high-precision tools. The company was founded in 2003.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 7, 2025 |
| -NT$0.19-224.7% vs estimate |
| NT$481.44M-2.74% vs estimate |
| Q4 2024 | Dec 31, 2024 | -NT$0.53-180.75% vs estimate | NT$502.22M-14.88% vs estimate |
|---|
| Q3 2024 | Sep 30, 2024 | -NT$0.88-345.09% vs estimate | NT$488.27M-8.39% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$182.50-NT$11.50 (-5.93%)
ACRO Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.13% below the high.
NT$33.20-NT$0.60 (-1.78%)
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
NT$68.20-NT$0.40 (-0.58%)
UnicoCell Biomed Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.82% below the high.
NT$43.50-NT$0.30 (-0.68%)
Orient EuroPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$24.60-NT$0.20 (-0.81%)
Formosa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.13% below the high.
NT$69.00-NT$0.50 (-0.72%)
ICARES Medicus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 16.9% below the high.
NT$30.95-NT$0.80 (-2.52%)
Senhwa Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.46% below the high.
NT$35.10-NT$1.00 (-2.77%)
Maxigen Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.33% below the high.
